Prosthetic heart valve having leaflet inflow below frame

Abstract
Embodiments of a prosthetic heart valve are disclosed. An implantable prosthetic valve can include an annular frame having an inflow end, an outflow end and a central longitudinal axis extending from the inflow end to the outflow end. The valve can include a valvular structure including two or more leaflets, each of the two or more leaflets having a leaflet inflow edge positioned at least partially outside of the frame and a leaflet outflow edge positioned within the frame, wherein at least a portion of each of the leaflet inflow edges is unsupported by the frame.
Description
FIELD

The present disclosure concerns embodiments of a prosthetic heart valve.


BACKGROUND

The human heart can suffer from various valvular diseases. These valvular diseases can result in significant malfunctioning of the heart and ultimately require replacement of the native valve with an artificial valve. There are a number of known artificial valves and a number of known methods of implanting these artificial valves in humans.


Various surgical techniques may be used to replace or repair a diseased or damaged valve. Due to stenosis and other heart valve diseases, thousands of patients undergo surgery each year wherein the defective native heart valve is replaced by a prosthetic valve. Another less drastic method for treating defective valves is through repair or reconstruction, which is typically used on minimally calcified valves. The problem with surgical therapy is the significant risk it imposes on these chronically ill patients with high morbidity and mortality rates associated with surgical repair.


When the native valve is replaced, surgical implantation of the prosthetic valve typically requires an open-chest surgery during which the heart is stopped and patient placed on cardiopulmonary bypass (a so-called “heart-lung machine”). In one common surgical procedure, the diseased native valve leaflets are excised and a prosthetic valve is sutured to the surrounding tissue at the valve annulus. Because of the trauma associated with the procedure and the attendant duration of extracorporeal blood circulation, some patients do not survive the surgical procedure or die shortly thereafter. It is well known that the risk to the patient increases with the amount of time required on extracorporeal circulation. Due to these risks, a substantial number of patients with defective native valves are deemed inoperable because their condition is too frail to withstand the procedure. By some estimates, more than 50% of the subjects suffering from valve stenosis who are older than 80 years cannot be operated on for valve replacement.


Because of the drawbacks associated with conventional open-heart surgery, percutaneous and minimally-invasive surgical approaches have become widely adopted in recent years. In one technique, a prosthetic valve is configured to be implanted in a much less invasive procedure by way of catheterization. For instance, U.S. Pat. Nos. 5,411,522 and 6,730,118, which are incorporated herein by reference, describe collapsible transcatheter heart valves that can be percutaneously introduced in a compressed state on a catheter and expanded in the desired position by balloon inflation or by utilization of a self-expanding frame or stent.


An important design parameter of a transcatheter heart valve is the amount of mechanical interaction between the prosthetic frame or stent and the native anatomy at the annulus and left ventricle outflow tract (“LVOT”) level. It is desirable to reduce tissue trauma and/or mechanical stress in the native anatomy to avoid procedural-related injuries, such as LVOT, aortic and/or annulus rupture, which may occur in the region of the aortic root and the LVOT during transcatheter aortic valve replacement.


SUMMARY

An exemplary embodiment of a prosthetic heart valve can include an annular frame having an inflow end, an outflow end and a central longitudinal axis extending from the inflow end to the outflow end. The frame can include a valvular structure including two or more leaflets, each of the two or more leaflets having a leaflet inflow edge positioned at least partially outside of the frame and a leaflet outflow edge positioned within the frame, wherein at least a portion of each of the leaflet inflow edges is unsupported by the frame. Some embodiments can include an inner skirt, wherein a first portion of the inner skirt extends circumferentially around the central longitudinal axis along an inner surface of the frame and a second portion of the inner skirt extends circumferentially around the central longitudinal axis outside of the frame. In some embodiments, the portions of the leaflet inflow edges unsupported by the frame are connected to the second portion of the inner skirt.


Additionally and/or alternatively, the inner skirt can include a first set of fibers that are sufficiently stiff to impede inward bending of the second portion due to systolic pressure gradient and blood flowing from the left ventricle to the aorta. In some embodiments, the first set of fibers run parallel to the central longitudinal axis. In some embodiments, the inner skirt includes a second set of fibers that run perpendicular to the first set of fibers, wherein the first set of fibers are stiffer than the second set of fibers. In some embodiments, the first set of fibers include monofilaments. In some embodiments, the portions of the leaflet inflow edges unsupported by the frame each include an apex portion of each leaflet. In some embodiments, the frame includes at least two rows of cells defining openings having a length in an axial direction and a length of the portion of the inflow edges unsupported by the frame is equal to or greater than the length of the openings. Additionally and/or alternatively, some embodiments can include an outer sealing member mounted on the outside of the frame.


Additionally and/or alternatively, some embodiments can include an outer support layer mounted on the outside of the frame having an inflow end portion that extends axially beyond the inflow end of the frame, and the portion of the leaflet inflow edges unsupported by the frame is connected to the inflow end portion of the outer support layer.


Some embodiments of an implantable prosthetic valve can include an annular frame having an inflow end, an outflow end and a central longitudinal axis extending from the inflow end to the outflow end, an inner skirt, wherein a first portion of the inner skirt extends circumferentially around the central longitudinal axis along an inner surface of the frame and a second portion of the inner skirt extends circumferentially around the central longitudinal axis outside of the frame and a valvular structure including two or more leaflets, each of the two or more leaflets having a leaflet inflow edge positioned at least partially outside of the frame and a leaflet outflow edge positioned within the frame, wherein at least a portion of each of the leaflet inflow edges are connected to the second portion of the inner skirt.


In some embodiments, the inner skirt includes a first set of fibers and a second set of fibers that runs perpendicular to the first set of fibers, wherein the first set of fibers is stiffer than the second set of fibers. In some embodiments, the frame includes a row of cells defining openings having a length in an axial direction and further wherein a length of the second portion is equal to or greater than the length of the openings. In some embodiments, an outer skirt can be connected to the second portion of the inner skirt. In some embodiments, the portions of the leaflet inflow edges unsupported by the frame include an apex portion of each leaflet.


Some embodiments of an implantable prosthetic valve can include an annular frame having an inflow end, an outflow end and a central longitudinal axis extending from the inflow end to the outflow end, a support layer, wherein a first portion of the support layer extends circumferentially around the central longitudinal axis along an outer surface of the frame and a second portion of the support layer extends circumferentially around the central longitudinal axis axially beyond the inflow end of the frame, and a valvular structure wherein at least a portion of the valvular structure is connected to the second portion of the support layer and is unsupported by the frame. In some embodiments, an outer skirt can be connected to the second portion of the support layer at an inflow end of the outer skirt. In some embodiments, the support layer includes a first set of fibers and a second set of fibers that runs perpendicular to the first set of fibers, wherein the first set of fibers is stiffer than the second set of fibers. In some embodiments, the valvular structure comprises a plurality of leaflets and the first set of fibers includes monofilaments. In some embodiments, the at least a portion of the valvular structure unsupported by the frame includes an apex portion of each leaflet.


The foregoing and other objects, features, and advantages of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a front view of an exemplary embodiment of a prosthetic heart valve.



FIG. 2 shows a side view of the prosthetic heart valve of FIG. 1 with the outer skirt removed to show an inner skirt and valvular structure mounted on the frame.



FIG. 3 shows a rotated front view of the prosthetic heart valve of FIG. 2.



FIG. 4 shows an enlarged, partial cross-sectional view of a prosthetic heart valve, according to one embodiment.



FIG. 5A shows an enlarged, partial cross-sectional view of a prosthetic heart valve, according to one embodiment.



FIG. 5B shows a side view of an exemplary support layer shown in flattened configuration.



FIG. 6 shows a top plan view of the prosthetic heart valve of FIG. 1.



FIG. 7 shows a side view of an exemplary inner skirt shown in flattened configuration.



FIG. 8 shows a side view of an exemplary leaflet shown in flattened configuration.



FIG. 9 shows a side view of an exemplary outer skirt shown in flattened configuration.



FIG. 10 shows a perspective view of an exemplary frame of the prosthetic heart valve of FIG. 1.



FIG. 11 shows a side view of the frame of FIG. 10 shown in flattened configuration.



FIG. 12 is a side view of the prosthetic valve of FIG. 1 in a collapsed configuration mounted on the balloon of a delivery apparatus.





DETAILED DESCRIPTION

For purposes of this description, certain aspects, advantages, and novel features of the embodiments of this disclosure are described herein. Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any particular embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


Although the operations of some of the disclosed methods are described in a particular, sequential order for convenient presentation, it should be understood that this manner of description encompasses rearrangement, unless a particular ordering is required by specific language. For example, operations described sequentially may in some cases be rearranged or performed concurrently. Moreover, for the sake of simplicity, the attached figures may not show the various ways in which the disclosed methods can be used in conjunction with other methods.


As used herein, the terms “a”, “an”, and “at least one” encompass one or more of the specified element. That is, if two of a particular element are present, one of these elements is also present and thus “an” element is present. The terms “a plurality of” and “plural” mean two or more of the specified element.


As used herein, the term “and/or” used between the last two of a list of elements means any one or more of the listed elements. For example, the phrase “A, B, and/or C” means “A”, “B,”, “C”, “A and B”, “A and C”, “B and C”, or “A, B, and C.”


As used herein, the term “coupled” generally means physically coupled or linked and does not exclude the presence of intermediate elements between the coupled items absent specific contrary language.



FIGS. 1 and 6 show side and top plan views, respectively, of a prosthetic heart valve 10 having an inflow end 80 and an outflow end 82, according to one embodiment. The illustrated prosthetic valve is adapted to be implanted in the native aortic annulus, although in other embodiments it can be adapted to be implanted in the other native annuluses of the heart (the mitral valve, pulmonary valve and triscupid valve). The prosthetic valve 10 can have one or more of the following components: a stent, or frame, 12, a valvular structure 14 and an inner skirt, or sealing member, 16. The valve 10 can also include an outer skirt, or sealing member 18.


The valvular structure 14 can comprise three leaflets 20, collectively forming a valvular structure, which can be arranged to collapse in a tricuspid arrangement, as best shown in FIG. 6. The lower edge of valvular structure 14 desirably has an undulating, curved scalloped shape. By forming the leaflets with this scalloped geometry, stresses on the leaflets are reduced, which in turn improves durability of the valve. Moreover, by virtue of the scalloped shape, folds and ripples at the belly of each leaflet (the central region of each leaflet), which can cause early calcification in those areas, can be eliminated or at least minimized. The scalloped geometry also reduces the amount of tissue material used to form the valvular structure 14, thereby allowing a smaller, more even crimped profile at the inflow end of the valve. The leaflets 20 can be formed of pericardial tissue (e.g., bovine pericardial tissue), biocompatible synthetic materials, or various other suitable natural or synthetic materials as known in the art and described in U.S. Pat. No. 6,730,118, which is incorporated by reference herein.


The bare frame 12 is shown in FIGS. 10 and 11. The frame 12 has an inflow end 22, an outflow end 24 and a central longitudinal axis 26 extending from the inflow end 22 to the outflow end 24. The frame 12 can be made of any of various suitable plastically-expandable materials (e.g., stainless steel, etc.) or self-expanding materials (e.g., Nitinol) as known in the art. When constructed of a plastically-expandable material, the frame 12 (and thus the prosthetic valve 10) can be crimped to a radially compressed state on a delivery catheter and then expanded inside a patient by an inflatable balloon or equivalent expansion mechanism. When constructed of a self-expandable material, the frame 12 (and thus the prosthetic valve 10) can be crimped to a radially compressed state and restrained in the compressed state by insertion into a sheath or equivalent mechanism of a delivery catheter. Once inside the body, the valve can be advanced from the delivery sheath, which allows the valve to expand to its functional size.


Suitable plastically-expandable materials that can be used to form the frame 12 include, without limitation, stainless steel, a nickel based alloy (e.g., a cobalt-chromium or a nickel-cobalt-chromium alloy), polymers, or combinations thereof. In particular embodiments, frame 12 is made of a nickel-cobalt-chromium-molybdenum alloy, such as MP35N™ (tradename of SPS Technologies), which is equivalent to UNS R30035 (covered by ASTM F562-02). MP35N™/UNS R30035 comprises 35% nickel, 35% cobalt, 20% chromium, and 10% molybdenum, by weight. It has been found that the use of MP35N to form frame 12 provides superior structural results over stainless steel. In particular, when MP35N is used as the frame material, less material is needed to achieve the same or better performance in radial and crush force resistance, fatigue resistances, and corrosion resistance. Moreover, since less material is required, the crimped profile of the frame can be reduced, thereby providing a lower profile valve assembly for percutaneous delivery to the treatment location in the body.


Referring to FIGS. 10 and 11, the frame 12 in the illustrated embodiment comprises a first, lower row I of angled struts 28 arranged end-to-end and extending circumferentially at the inflow end of the frame; a second row II of circumferentially extending, angled struts 30; a third row III of circumferentially extending, angled struts 32; and a forth row IV of circumferentially extending, angled struts 34 at the outflow end of the frame 12. The forth row IV of angled struts 34 can be connected to the third row III of angled struts 32 by a plurality of axially extending window frame portions 36 (which define commissure windows 38) and a plurality of axially extending struts 40. Each axial strut 40 and each frame portion 36 extends from a location defined by the convergence of the lower ends of two angled struts 34 to another location defined by the convergence of the upper ends of two angled struts 32.


Each commissure window frame portion 36 mounts a respective commissure 74 of the leaflet structure 14. As can be seen, each frame portion 36 is secured at its upper and lower ends to the adjacent rows of struts to provide a robust configuration that enhances fatigue resistance under cyclic loading of the valve compared to known cantilevered struts for supporting the commissures of the leaflet structure. This configuration enables a reduction in the frame wall thickness to achieve a smaller crimped diameter of the valve. In particular embodiments, the thickness of the frame 12 measured between the inner diameter and outer diameter is about 0.48 mm or less.


The struts and frame portions of the frame collectively define a plurality of open cells of the frame. At the inflow end 22 of the frame 12, struts 28 and struts 30 define a lower row of cells defining openings 42. The second and third rows of struts 30 and 32, respectively, define an intermediate row of cells defining openings 44. The third and fourth rows of struts 32 and 34, along with frame portions 36 and struts 40, define an upper row of cells defining openings 46. The openings 46 are relatively large and are sized to allow portions of the valvular structure 14 to protrude, or bulge, into and/or through the openings 46 when the frame 12 is crimped in order to minimize the crimping profile.


The frame 12 can have other configurations or shapes in other embodiments. For example, the frame 12 can comprise a plurality of circumferential rows of angled struts 28, 30, 32, 34 connected directly to each other without vertical struts 40 or frame portions 36 between adjacent rows of struts, or the rows of struts 28, 30, 32, 34 can be evenly spaced with vertical struts 40 and/or frame portions 36 extending therebetween. In other embodiments, the frame can comprise a braided structure braided from one or more metal wires.


The inner skirt 16 can have a plurality of functions, which can include to assist in securing the valvular structure 14 and/or the outer skirt to the frame 12 and to assist in forming a good seal between the valve 10 and the native annulus by blocking the flow of blood below the lower edges of the leaflets. The inner skirt 16 can comprise a tough, tear resistant material such as polyethylene terephthalate (PET), although various other synthetic or natural materials can be used. The thickness of the skirt desirably is less than 6 mil or 0.15 mm, and desirably less than 4 mil or 0.10 mm, and even more desirably about 2 mil or 0.05 mm. In particular embodiments, the skirt 16 can have a variable thickness, for example, the skirt can be thicker at its edges than at its center. In one implementation, the skirt 16 can comprise a PET skirt having a thickness of about 0.07 mm at its edges and about 0.06 mm at its center. The thinner skirt can provide for better crimping performances while still providing good perivalvular sealing.


As noted above, the valvular structure 14 in the illustrated embodiment includes three flexible leaflets 20 (although a greater or fewer number of leaflets can be used). An exemplary leaflet 20 is shown in FIG. 8. Each leaflet 20 can have a reinforcing strip 58 secured (e.g., sewn) to the inner surface of the lower edge portion 56. Each leaflet 20 in the illustrated configuration can have an upper (outflow) free edge 48 extending between opposing upper tabs 50 on opposite sides of the leaflet 20. Below each upper tab 50 there can be a notch 52 separating the upper tab 50 from a corresponding lower tab 54. The lower (inflow) edge portion 56 of the leaflet extending between respective ends of the lower tabs 54 can include vertical, or axial, edge portions 60 on opposites of the leaflets extending downwardly from corresponding lower tabs 54 and a substantially V-shaped, intermediate edge portion 62 having a smooth, curved apex portion 64 at the lower end of the leaflet and a pair of oblique portions 66 that extend between the axial edge portions 60 and the apex portion 64. The oblique portions 66 can have a greater radius of curvature than the apex portion 64. The leaflets can have various other shapes and/or configurations in other embodiments. For example, the leaflets need not have a V-shaped or scalloped inflow edges and instead each leaflet can have a square or rectangular shape defining a straight inflow edge.


The leaflets 20 can be sutured together to form the assembled valvular structure 14, which can then be secured to the frame 12. For example, the leaflets 20 can be secured to one another at their adjacent sides to form commissures 74 of the valvular structure. A plurality of flexible connectors (not shown) can be used to interconnect pairs of adjacent sides of the leaflets and to mount the leaflets to the commissure window frame portions 30, as further discussed below. The leaflets 20 can additionally and/or alternatively be secured together via adjacent sub-commissure portions (not shown) of two leaflets that can be sutured directly to each other.



FIGS. 2 and 3 show the frame 12, the valvular structure 14 and the inner skirt 16 after securing the valvular structure 14 to the inner skirt 16 and then securing these components to the frame 12. The inner skirt 16 can be secured to the inside of frame 12 via sutures 68. The valvular structure 14 can be attached to the inner skirt 16 via the one or more thin PET reinforcing strips 58 along the lower (inflow) edge portions 56 of the leaflets 20. The reinforcing strips 58 collectively can form a sleeve, which can enable a secure suturing and protect the pericardial tissue of the valvular structure 14 from tears. Valvular structure 14 can be sandwiched between the inner skirt 16 and the thin PET strips 58. Sutures 70, which secure the PET strips and the valvular structure 14 to inner skirt 16, can be any suitable suture, such as an Ethibond suture. Sutures 70 desirably track the curvature of the bottom edge of valvular structure 14 and are collectible referred to as scallop line 72. In lieu of or in addition to the strips 58 along the inner surface of the leaflets, reinforcing strips 58 can be positioned between the inner skirt 16 and the inflow edge portions 56 of the leaflets (FIG. 4).


As shown in FIGS. 2 and 3, portions of the inflow edges 56 of the leaflets 56 are positioned between diagonal lines defined by the struts 28, 30 of the first and second circumferential rows of the struts. In some embodiments, the inflow edges 56 of the leaflets 20 can track the diagonal lines defined by the struts 28, 30. In such embodiments, the portions of the inflow edges 56 above the inflow end of the frame can be sutured to adjacent struts 28, 30.


The outflow end portion of the valvular structure 14 can be secured to the window frame portions 36. In particular, each leaflet 20 can have opposing tab portions, each of which is paired with an adjacent tab portion of another leaflet to form a commissure 74. As best shown in FIG. 1, the commissures 74 can extend through windows 38 of respective window frame portions 36 and sutured in place. Further details of the commissures 74 and a method for assembling the commissures and mounting them to the frame are disclosed in U.S. Publication No. 2012/0123529, which is incorporated herein by reference. The inner skirt 16 can terminate short of the window frame portions 36 and does not extend the entire length of the frame 12. In alternative embodiments, the inner skirt 16 can extend the entire length or substantially the entire length of the frame 12 from below the inflow end 22 to the outflow end 24. In other embodiments, the inner skirt 16 can extend up to the second row of angled struts 30.


In particular embodiments, and as shown in FIGS. 1-3, the valvular structure 14 can extend axially beyond the inflow end 22 of the frame 12 such that at least a portion of the inflow edges 56 of each leaflet is not supported by the frame 12. For example, the apex portions 64 of the leaflets 20 can extend axially beyond and can be unsupported by the frame 12. Additionally and/or alternatively, the oblique portions 66 and the apex portions 64 can extend axially beyond and can be unsupported by the frame 12. Additionally and/or alternatively, the intermediate portions 62, the oblique portions 66 and the apex portions 64 can extend axially beyond and can be unsupported by the frame 12. Additionally and/or alternatively, the vertical edge portions 60, the intermediate portions 62, the oblique portions 66 and the apex portions 64 can extend axially beyond and can be unsupported by the frame 12. In some embodiments, a portion 76 of each leaflet extends below the inflow end 22 of the frame a length L1 that is equal to or greater than a length L2 of each cell opening 42 in the axial direction. In some embodiments, L1 can range between about 2 mm to 8 mm in length, with 4 mm being a specific example. Additionally and/or alternatively, L1 can be up to 12 mm. In some embodiments, L2 can range between about 3 mm to 5 mm in length, with 4 mm being a specific example. Additionally and/or alternatively, L2 can range between 2 mm to 7 mm.


Additionally and/or alternatively, as shown in FIG. 4, the inner skirt 16 can include a first portion 84, also referred to as supported portion, that extends circumferentially around the central longitudinal axis of the prosthetic valve along an inner surface of the frame 12 and a second portion, also referred to as unsupported portion 78, at the inflow end 80 of the prosthetic valve 10. The unsupported portion 78 is unsupported by the frame 12. The unsupported portion 78 can extend circumferentially around the central longitudinal axis of the prosthetic valve to form an unsupported circumference at the inflow end 80. As shown in FIG. 4, the portion of each leaflet 20 that is not supported by the frame 12 can be connected to the inner skirt 16. In some embodiments, a length L3 of the unsupported portion 78 is equal to or greater than the length L2 of the openings 42. In some embodiments, L3 can be 2 mm to 3 mm longer than L1. Additionally and/or alternatively, L3 can range from the same length as L1 to 5 mm longer than L1. In some embodiments, L3 can range between about 2 mm to 11 mm in length, with 6 mm being a specific example. Additionally and/or alternatively, L3 can be up to 15 mm.


In some embodiments, as best shown in FIG. 7, the inner skirt 16 can be woven from a first set of fibers 86, or yarns or strands, and a second set of fibers 88, or yarns or strands. The first and set of fibers 86, 88 can run perpendicular and parallel, respectively, to upper 90 and lower 92 edges of the inner skirt 16, or alternatively, they can extend at angles between 0 and 90 degrees relative to the upper and lower edges 90, 92 of the inner skirt 16. The first set of fibers 86 can be stiffer than the second set of fibers 88. For example the first set of fibers 86 can include monofilaments. The extra stiffness of the first set of fibers 86 can provide support to the prosthetic leaflets 20 during systole. For example, the first set of fibers 86 can reinforce the inner skirt 16 to impede inward and/or outward folding or bending of the unsupported portion 78 of the inner skirt and/or the unsupported portions of 76 of the leaflets that are unsupported by the frame 12 due to systolic pressure gradient and blood flowing from the left ventricle to the aorta. In other embodiments, the fibers 86 can be thicker than the fibers 88 and/or axially extending reinforcing wires (extending in the same direction as fibers 86) can be woven or secured to the skirt to increase the axial stiffness of the skirt. The reinforcing wires can be metal wires formed from a suitable biocompatible metal, such as stainless steel or Nitinol.


In some embodiments, the first set of fibers 86 and the second set of fibers 88 can extend at angles of about 45 degrees relative to the upper and lower edges. The inner skirt 16 can be formed by weaving the fibers at 45 degree angles relative to the upper and lower edges of the fabric. Alternatively, the skirt can be diagonally cut from a vertically woven fabric (where the fibers extend perpendicular to the edges of the material) such that the fibers extend at 45 degree angles relative to the cut upper and lower edges of the skirt. The opposing short edges of the inner skirt can be non-perpendicular to the upper and lower edges.



FIG. 9 shows a flattened view of the outer skirt 18 prior to its attachment to the inner skirt 16 and the frame 12. The outer skirt 18 can be laser cut or otherwise formed from a strong, durable piece of material, such as woven PET, although other synthetic or natural materials can be used. The outer skirt 18 can have a substantially straight lower edge 94 and an upper edge 96 defining a plurality of alternating projections 98 and notches 100. Alternatively, the lower edge 94 of the outer skirt 18 can include openings similar to those on the upper edge, or can include a separate row of holes adjacent to the straight lower edge 94. As best shown in FIG. 1, the lower edge 94 of the outer skirt 18 can be secured to the lower edge 92 of the inner skirt 16 at the inflow end of the prosthetic valve, such as by sutures, welding, and/or an adhesive. In particular embodiments, the lower edge 94 of the outer skirt 18 is tightly sutured or otherwise secured (e.g., by welding or an adhesive) to the inner skirt 16.


The upper edge 96 of the outer skirt 18 desirably is secured to the frame 12 and/or the inner skirt 16 at spaced-apart locations around the circumference of the frame 12. In the illustrated embodiment, for example, the projections 98 of the outer skirt can be sutured to the struts of the frame 12 and/or the inner skirt 16. As shown, the corners of the projections 98 of the outer skirt 18 can be folded over respective struts and secured with sutures 104 (FIG. 1). The notches 100 can remain unattached to the inner skirt 16 and the frame 12. When the valve 10 is deployed within the body (e.g., within the native aortic valve), the outer skirt 18 can cooperate with the inner skirt 16 to prevent or at least minimize paravalvular leakage.


The absence of metal components of the frame or other rigid members along the inflow end portion of the prosthetic valve advantageously reduces mechanical compression of the native valve annulus (e.g., the aortic annulus) and the left ventricular outflow tract (when implanted in the aortic position), thus reducing the risk of trauma to the surrounding tissue.


As shown in FIG. 5A, some embodiments of a prosthetic valve 10 do not include an inner skirt 16 and instead can include a support layer 110 disposed radially between the frame 12 and the outer skirt 18. In this manner, the support layer 110 and the outer skirt 18 form an outer sealing member with the support layer 110 forming an inner wall or layer of the sealing member and the outer skirt forming an outer wall or layer of the sealing member. A first portion 112 of the support layer 110 can extend circumferentially around the central longitudinal axis of the prosthetic valve along an outer surface of the frame 12 and a second portion 114 of the support layer 110 can extend circumferentially around the central longitudinal axis axially beyond the inflow end 22 of the frame. The unsupported portions 76 of the leaflets can be connected to the support layer 110 (e.g., by sutures, an adhesive, and/or welding) similar to the manner that the leaflets are connected to the inner skirt in the embodiment of FIG. 4. For example, the inflow edge portions 56 can be sutured to reinforcing strips 58 and the support layer 110 with the inflow edge portions 56 sandwiched between the support layer 110 and the reinforcing strips 58. Additionally and/or alternatively, reinforcing strips 58 can be positioned between the inflow edge portions 56 and the support layer 110 with sutures securing these layers together. Additionally and/or alternatively, the outer skirt 18 can be connected to the second portion 114 of the support layer (e.g., by sutures, an adhesive, and/or welding).


The support layer 110 can have the same or similar size and shape as the inner skirt 16 and can be made of the same or similar materials as the inner skirt 16. For example, as shown in FIG. 5B, the support layer 110 can be woven from a first set of fibers 116 and a second set of fibers 118, or yarns or strands. The first and second set of fibers 116, 118 can run perpendicular and parallel, respectively, to upper and lower edges 120, 122 of the support layer 110, or alternatively, they can extend at angles between 0 and 90 degrees relative to the upper and lower edges 120, 122 of the support layer. The first set of fibers 116 can be stiffer than the second set of fibers 118. For example the first set of fibers 116 can include monofilaments, reinforcing wires and/or thicker fibers than the fibers 118. The extra stiffness of the first set of fibers 116 can provide support to the prosthetic leaflets 20 during systole. For example, the first set of fibers 116 can reinforce the support layer 110 to impede inward and/or outward folding or bending of the lower portion 114 and the unsupported portions 76 of the leaflets due to systolic pressure gradient and blood flowing from the left ventricle to the aorta.


In alternative embodiments, the prosthetic valve 10 can include an inner skirt 16 and an outer support layer 110.



FIG. 12 shows the prosthetic valve 10 in a radially compressed state for delivery into a patient's body on a delivery catheter 200. As shown, the prosthetic valve 10 can be crimped on a balloon 202 of the delivery catheter 200. In the delivery configuration, the outer skirt 18 can be folded against the outer surface of the frame 12. When deployed inside the body (e.g., after being released from the sheath of the delivery catheter), the stent 12 and the outer skirt 18 can radially expand, such as by inflating the balloon 202.


In view of the many possible embodiments to which the principles of the disclosed technology may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the disclosure and should not be taken as limiting the scope of the disclosure. Rather, the scope of the disclosure is defined by the following claims. I therefore claim as my disclosure all that comes within the scope and spirit of these claims.

Claims
  • 1. An implantable prosthetic valve for replacing a native valve of the heart, the prosthetic valve comprising: an annular frame having an inflow end, an outflow end and a central longitudinal axis extending from the inflow end to the outflow end, wherein the frame is expandable from a radially compressed state to a radially expanded state in which the prosthetic valve engages an annulus of the native valve;a valvular structure including two or more leaflets, each of the two or more leaflets having a leaflet inflow edge positioned at least partially outside of the frame and a leaflet outflow edge positioned within the frame, wherein at least a portion of each of the leaflet inflow edges is unsupported by the frame; andan inner skirt, wherein a first portion of the inner skirt extends circumferentially around the central longitudinal axis along an inner surface of the frame and a second portion of the inner skirt extends circumferentially around the central longitudinal axis outside of the frame.
  • 2. The valve of claim 1, wherein the inner skirt includes a first set of fibers that are sufficiently stiff to impede inward bending of the second portion due to systolic pressure gradient and blood flowing from the left ventricle to the aorta.
  • 3. The valve of claim 2, wherein the first set of fibers run parallel to the central longitudinal axis.
  • 4. The valve of claim 2, wherein the inner skirt includes a second set of fibers that run perpendicular to the first set of fibers, wherein the first set of fibers are stiffer than the second set of fibers.
  • 5. The valve of claim 2, wherein the first set of fibers include monofilaments.
  • 6. The valve of claim 1, wherein the portions of the leaflet inflow edges unsupported by the frame each include an apex portion of each leaflet.
  • 7. The valve of claim 1, wherein the frame includes at least two rows of cells extending circumferentially around the central longitudinal axis and wherein the cells of the at least two rows of cells define openings, the openings having a length in an axial direction and wherein a length of the portion of the inflow edges unsupported by the frame is equal to or greater than the length of the openings.
  • 8. The valve of claim 1, further comprising an outer sealing member mounted on the frame.
  • 9. An implantable prosthetic valve for replacing a native valve of the heart, the prosthetic valve comprising: an annular frame having an inflow end, an outflow end and a central longitudinal axis extending from the inflow end to the outflow end, wherein the frame is expandable from a radially compressed state to a radially expanded state in which the prosthetic valve engages an annulus of the native valve;an inner skirt, wherein a first portion of the inner skirt extends circumferentially around the central longitudinal axis along an inner surface of the frame and a second portion of the inner skirt extends circumferentially around the central longitudinal axis outside of the frame; anda valvular structure including two or more leaflets, each of the two or more leaflets having a leaflet inflow edge positioned at least partially outside of the frame and a leaflet outflow edge positioned within the frame, wherein at least a portion of each of the leaflet inflow edges are connected to the second portion of the inner skirt.
  • 10. The valve of claim 9, wherein the inner skirt includes a first set of fibers and a second set of fibers that runs perpendicular to the first set of fibers, wherein the first set of fibers is stiffer than the second set of fibers.
  • 11. The valve of claim 9, wherein the frame includes a row of cells defining openings having a length in an axial direction and further wherein a length of the second portion is equal to or greater than the length of the openings.
  • 12. The valve of claim 9, further comprising an outer skirt connected to the second portion of the inner skirt.
  • 13. The valve of claim 9, wherein the portions of the leaflet inflow edges unsupported by the frame include an apex portion of each leaflet.
  • 14. An implantable prosthetic valve for replacing a native valve of the heart, the prosthetic valve comprising:an annular frame having an inflow end, an outflow end and a central longitudinal axis extending from the inflow end to the outflow end, wherein the frame is expandable from a radially compressed state to a radially expanded state in which the prosthetic valve engages an annulus of the native valve; anda valvular structure including two or more leaflets, each of the two or more leaflets having a leaflet inflow edge positioned at least partially outside of the frame and a leaflet outflow edge positioned within the frame, wherein at least a portion of each of the leaflet inflow edges is unsupported by the frame;wherein the frame includes at least two rows of cells extending circumferentially around the central longitudinal axis and wherein the cells of the at least two rows of cells define openings, the openings having a length in an axial direction and wherein a length of the portion of the inflow edges unsupported by the frame is equal to or greater than the length of the openings.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 15/808,599, filed Nov. 9, 2017, which claims the benefit of U.S. Provisional Patent Application No. 62/423,599, filed Nov. 17, 2016, both of which applications are incorporated herein by reference.

US Referenced Citations (294)
Number Name Date Kind
3409013 Berry Nov 1968 A
3548417 Kisher Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
RE30912 Hancock Apr 1982 E
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4441216 Ionescu et al. Apr 1984 A
4470157 Love Sep 1984 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4820299 Philippe et al. Apr 1989 A
4829990 Thuroff et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne Oct 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5332402 Teitelbaum Jul 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411552 Andersen et al. May 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5558644 Boyd et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5584803 Stevens et al. Dec 1996 A
5591185 Kilmer et al. Jan 1997 A
5591195 Taheri et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5628792 Lentell May 1997 A
5639274 Fischell et al. Jun 1997 A
5665115 Cragg Sep 1997 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5800508 Goicoechea et al. Sep 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
6027525 Suh et al. Feb 2000 A
6132473 Williams et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6338740 Carpentier Jan 2002 B1
6350277 Kocur Feb 2002 B1
6352547 Brown et al. Mar 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440764 Focht et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6527979 Constantz et al. Mar 2003 B2
6569196 Vesely May 2003 B1
6582462 Andersen et al. Jun 2003 B1
6605112 Moll et al. Aug 2003 B1
6652578 Bailey et al. Nov 2003 B2
6689123 Pinchasik Feb 2004 B2
6716244 Klaco Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6767362 Schreck Jul 2004 B2
6769161 Brown et al. Aug 2004 B2
6783542 Eidenschink Aug 2004 B2
6830584 Seguin Dec 2004 B1
6878162 Bales et al. Apr 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
6936067 Buchanan Aug 2005 B2
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7096554 Austin et al. Aug 2006 B2
7225518 Eidenschink et al. Jun 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7316710 Cheng et al. Jan 2008 B1
7318278 Zhang et al. Jan 2008 B2
7374571 Pease et al. May 2008 B2
7393360 Spenser et al. Jul 2008 B2
7462191 Spenser et al. Dec 2008 B2
7510575 Spenser et al. Mar 2009 B2
7563280 Anderson et al. Jul 2009 B2
7585321 Cribier Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7618447 Case et al. Nov 2009 B2
7655034 Mitchell et al. Feb 2010 B2
7785366 Maurer et al. Aug 2010 B2
7959665 Pienknagura Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7993394 Hariton et al. Aug 2011 B2
8029556 Rowe Oct 2011 B2
8075611 Millwee et al. Dec 2011 B2
8128686 Paul, Jr. et al. Mar 2012 B2
8167932 Bourang et al. May 2012 B2
8291570 Eidenschink et al. Oct 2012 B2
8348998 Pintor et al. Jan 2013 B2
8449606 Eliasen et al. May 2013 B2
8454685 Hariton et al. Jun 2013 B2
8652203 Quadri et al. Feb 2014 B2
8747463 Fogarty et al. Jun 2014 B2
9078781 Ryan et al. Jul 2015 B2
20010021872 Bailey et al. Sep 2001 A1
20020026094 Roth Feb 2002 A1
20020032481 Gabbay Mar 2002 A1
20020138135 Duerig et al. Sep 2002 A1
20020143390 Ishii Oct 2002 A1
20020173842 Buchanan Nov 2002 A1
20030014105 Cao Jan 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030100939 Yodat et al. May 2003 A1
20030158597 Quiachon et al. Aug 2003 A1
20030212454 Scott et al. Nov 2003 A1
20040024452 Kruse et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040260389 Case et al. Dec 2004 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050075725 Rowe Apr 2005 A1
20050075728 Nguyen et al. Apr 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050137687 Salahieh Jun 2005 A1
20050188525 Weber et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20060004469 Sokel Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060074484 Huber Apr 2006 A1
20060108090 Ederer et al. May 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060183383 Asmus et al. Aug 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070005131 Taylor Jan 2007 A1
20070010876 Salahieh et al. Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070112422 Dehdashtian May 2007 A1
20070162102 Ryan et al. Jul 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070203576 Lee et al. Aug 2007 A1
20070208550 Cao et al. Sep 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070260305 Drews et al. Nov 2007 A1
20070265700 Eliasen et al. Nov 2007 A1
20080021546 Patz et al. Jan 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080183271 Frawley et al. Jul 2008 A1
20080208327 Rowe Aug 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080275537 Limon Nov 2008 A1
20080294248 Yang et al. Nov 2008 A1
20090118826 Khaghani May 2009 A1
20090125118 Gong May 2009 A1
20090157175 Benichou Jun 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287296 Manasse Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090299452 Eidenschink et al. Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100049313 Alon et al. Feb 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100145438 Barone Jun 2010 A1
20100168844 Toomes et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100198347 Zakay et al. Aug 2010 A1
20100204781 Alkhatib Aug 2010 A1
20110004299 Essinger et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110066224 White Mar 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110319991 Hariton et al. Dec 2011 A1
20120089223 Nguyen et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120123529 Levi et al. May 2012 A1
20120171917 Rasmussen et al. Jul 2012 A1
20120259409 Nguyen et al. Oct 2012 A1
20130023985 Khairkhahan et al. Jan 2013 A1
20130046373 Cartledge et al. Feb 2013 A1
20130150956 Yohanan et al. Jun 2013 A1
20130166017 Cartledge et al. Jun 2013 A1
20130190857 Mitra et al. Jul 2013 A1
20130274873 Delaloye et al. Oct 2013 A1
20130310926 Hariton Nov 2013 A1
20130317598 Rowe et al. Nov 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20140194981 Menk et al. Jul 2014 A1
20140200661 Pintor et al. Jul 2014 A1
20140209238 Bonyuet et al. Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140228945 Valdez et al. Aug 2014 A1
20140277417 Schraut et al. Sep 2014 A1
20140277419 Garde et al. Sep 2014 A1
20140277424 Oslund Sep 2014 A1
20140277563 White Sep 2014 A1
20140296962 Cartledge et al. Oct 2014 A1
20140330372 Weston et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20140343671 Yohanan et al. Nov 2014 A1
20140350667 Braido et al. Nov 2014 A1
20150073545 Braido Mar 2015 A1
20150073546 Braido Mar 2015 A1
20150135506 White May 2015 A1
20150157455 Hoang et al. Jun 2015 A1
20150320556 Levi et al. Nov 2015 A1
20170014229 Nguyen-Thien-Nhon et al. Jan 2017 A1
20180028310 Gurovich et al. Feb 2018 A1
20180153689 Maimon et al. Jun 2018 A1
20180325665 Gurovich et al. Nov 2018 A1
20180344456 Barash et al. Dec 2018 A1
Foreign Referenced Citations (72)
Number Date Country
0144167 Sep 1903 DE
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
0103546 Mar 1984 EP
0850607 Jul 1998 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1570809 Sep 2005 EP
2788217 Jul 2000 FR
2815844 May 2002 FR
2056023 Mar 1981 GB
1271508 Nov 1986 SU
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9724080 Jul 1997 WO
9829057 Jul 1998 WO
9930646 Jun 1999 WO
9933414 Jul 1999 WO
0018333 Apr 2000 WO
0041652 Jul 2000 WO
0135878 May 2001 WO
0149213 Jul 2001 WO
0154624 Aug 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
0047139 Sep 2001 WO
0164137 Sep 2001 WO
0176510 Oct 2001 WO
0222054 Mar 2002 WO
0236048 May 2002 WO
0241789 May 2002 WO
0243620 Jun 2002 WO
0247575 Jun 2002 WO
0249540 Jun 2002 WO
03047468 Jun 2003 WO
2005034812 Apr 2005 WO
2005055883 Jun 2005 WO
2005084595 Sep 2005 WO
2006014233 Feb 2006 WO
2006032051 Mar 2006 WO
2006034008 Mar 2006 WO
2006111391 Oct 2006 WO
2006127089 Nov 2006 WO
2006138173 Dec 2006 WO
2005102015 Apr 2007 WO
2007047488 Apr 2007 WO
2007067942 Jun 2007 WO
2007097983 Aug 2007 WO
2008005405 Jan 2008 WO
2008015257 Feb 2008 WO
2008035337 Mar 2008 WO
2008091515 Jul 2008 WO
2008147964 Dec 2008 WO
2008150529 Dec 2008 WO
2009033469 Mar 2009 WO
2009042196 Apr 2009 WO
2009053497 Apr 2009 WO
2009061389 May 2009 WO
2009116041 Sep 2009 WO
2009149462 Dec 2009 WO
2010011699 Jan 2010 WO
2010121076 Oct 2010 WO
2013106585 Jul 2013 WO
2015085218 Jun 2015 WO
Non-Patent Literature Citations (9)
Entry
H.R. Andersen, et al. “Transluminal Implantation of Artificial Heart Valve. Description of a New Expandable Aortic Valve and Initial Results with implantation by Catheter Technique in Closed Chest Pig,” European Heart Journal, No. 13. pp. 704-708. 1992.
H.R. Andersen “History of Percutaneous Aortic Valve Prosthesis,” Herz No. 34. pp. 343-346. 2009.
Pavcnik, et al. “Development and initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology, vol. 183, No. 1 pp. 151-154. 1992.
Bailey, S. “Percutaneous Expandable Prosthetic Valves,” Textbook of Interventional Cardiology vol. 2, 2nd Ed. pp. 1268-1276. 1994.
Al-Khaja, et al. “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, vol. 3. pp. 305-311. 1989.
Ross, “Aortic Valve Surgery,” At a meeting of the Council on Aug. 4, 1966. pp. 192-197.
Sabbah, et al. “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Journal of Cardiac Surgery, vol. 4, No. 4. pp. 302-309. 1989.
Wheatley, “Valve Prostheses,” Operative Surgery, 4th ed. pp. 415-424. 1986.
Uchida, “Modifications of Gianturco Expandable Wire Stents,” American Journal of Roentgenology, vol. 150. pp. 1185-1187. 1986.
Related Publications (1)
Number Date Country
20200078168 A1 Mar 2020 US
Provisional Applications (1)
Number Date Country
62423599 Nov 2016 US
Continuations (1)
Number Date Country
Parent 15808599 Nov 2017 US
Child 16674357 US